irix-8k_20150806.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

 

FORM 8‑K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported)

 

August 6, 2015

 

 

 

IRIDEX CORPORATION

(Exact name of registrant as specified in its charter)

 

Delaware

 

0-27598

 

77-0210467

(State or other jurisdiction of incorporation)

 

(Commission File Number)

 

(IRS Employer
Identification No.)

 

1212 Terra Bella Avenue

Mountain View, California 94043

(Address of principal executive offices, including zip code)

 

(650) 940-4700

(Registrant’s telephone number, including area code)

 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[  ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 



Item 2.02.Results of Operations and Financial Condition.

On August 6, 2015, IRIDEX Corporation issued a press release discussing its financial results for its second fiscal quarter of 2015, which ended July 4, 2015.  The press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01.Financial Statements and Exhibits.

(d)Exhibits

 

Exhibit No.

 

Description

99.1

 

Press Release dated August 6, 2015.

 

 



SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

IRIDEX CORPORATION

 

 

 

 

By:

/s/ James H. Mackaness

 

 

James H. Mackaness

Chief Operating Officer and Chief Financial Officer

 

Date:  August 6, 2015

 

 


EXHIBIT INDEX

 

Exhibit No.

 

Description

99.1

 

Press Release dated August 6, 2015.

 

 

irix-ex991_6.htm

Exhibit 99.1

 

FOR IMMEDIATE RELEASE

IRIDEX Reports 2015 Second Quarter, Six-Month Results

Mountain View, CA. – August 6, 2015 – IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the second quarter and six months ended July 4, 2015.

Revenues were $9.0 million in the second quarter of 2015 compared to $10.6 million in the 2014 second quarter.  For the first six months of 2015, revenues were $19.8 million compared to $20.9 million in the prior year period.

Gross margin for the 2015 second quarter was 46.7% compared to 50.0% in the second quarter of the prior year.

In the 2015 second quarter, the operating loss was $0.7 million compared to operating income of $0.4 million in the 2014 second quarter.

Net loss for the second quarter of 2015 was $0.7 million, or $0.07 loss per share, compared to net income of $0.3 million, or $0.03 per diluted share, in the prior year period.  Net loss for the first six months of 2015 was $0.4 million, or $0.04 loss per share, compared to net income of $0.8 million, or $0.07 per diluted share, in the first six months of 2014.

Guidance: For the 2015 third quarter, the Company anticipates revenue of $9.7 million to $10.0 million, gross margin is anticipated to come in between 47% and 49%, and operating expenses are expected to be $4.9 million to $5.1 million.

President and CEO Will Moore said, “Demand for our products remained strong during the quarter, however, as previously announced, supply chain difficulties occurred during the quarter as we ramped up production for certain legacy and new product offerings which impacted our shipments.  We have taken corrective actions and anticipate these issues will be resolved by the end of summer.”

“The launch of our Cyclo G6™ Glaucoma laser platform is going very well. The early results of patients undergoing the MicroPulse® P3 procedure continue to be impressive and a number of the early sites are already reordering the single use probes indicating good procedural volumes, and we have even seen a couple of the early sites order additional lasers,” continued Moore.  “We believe the Cyclo G6 will provide a revenue growth catalyst for 2016 and beyond.”

Share Repurchase Program

As of July 20, 2015, the Company had satisfied its share repurchase program established a year ago, buying approximately 367,000 shares at an average price of $8.17.  Effective today, the IRIDEX Board of Directors established a new share repurchase program, allowing the purchase of up to $2.0 million worth of the Company’s common stock over the next 12 months.


Conference Call

IRIDEX management will conduct a conference call later today, Thursday, August 6, 2015, at 5:00 pm Eastern Time.  Interested parties may access the live conference call by dialing (877) 407-0784 (US) or (201) 689-8560 (International) and requesting the IRIDEX 2015 Second Quarter Results Conference Call, or by visiting the Company’s website at www.iridex.com.  A telephone replay will be available beginning on Thursday, August 6, 2015 through Thursday, August 13, 2015 by dialing (877) 870-5176 (US) or (858) 384-5517 (International) and entering Replay Pin # 13614233.  In addition, later today an archived version of the webcast will be available on the Company’s website at www.iridex.com.

About IRIDEX

IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. We maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. IRIDEX is dedicated to a standard of excellence, offering superior technology for superior results. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 70 independent distributors into over 100 countries. For further information, visit the IRIDEX website at http://www.iridex.com/.

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, including those statements concerning its anticipated revenues, the impact of future changes in currency exchange rates, future demand and order levels for the Company’s products, the timing and outcome of any steps that the Company may take to address supply chain issues, the adoption and effect of Company products, including the Cyclo G6™ Glaucoma laser platform, on our results, the markets in which the Company operates, trends in treatment and product adoption and usage, product plans and future product releases, the Company’s guidance concerning fiscal 2015 third quarter results, including anticipated ranges of revenue, gross margin, operating expenses and gross margin rates, the Company’s share repurchase program, and the Company’s strategic plans and objectives. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended January 3, 2015, which was filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.

 

 

Company Contact:

Investor Relations Contact:

Jim Mackaness

Matt Clawson

Chief Financial Officer

Pure Communications

& Chief Operating Officer

949-370-8500

650-940-4700

matt@purecommunicationsinc.com

 

 

TABLES FOLLOW


IRIDEX Corporation

Condensed Consolidated Statements of Operations

(In thousands, except per share data)

(unaudited)

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

July 4,

 

 

June 28,

 

 

July 4,

 

 

June 28,

 

 

 

2015

 

 

2014

 

 

2015

 

 

2014

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total revenues

 

$

9,033

 

 

$

10,589

 

 

$

19,829

 

 

$

20,918

 

Cost of revenues

 

 

4,816

 

 

 

5,289

 

 

 

10,202

 

 

 

10,563

 

Gross profit

 

 

4,217

 

 

 

5,300

 

 

 

9,627

 

 

 

10,355

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

1,482

 

 

 

1,306

 

 

 

2,763

 

 

 

2,500

 

Sales and marketing

 

 

2,158

 

 

 

2,056

 

 

 

4,229

 

 

 

3,804

 

General and administrative

 

 

1,324

 

 

 

1,538

 

 

 

2,979

 

 

 

3,054

 

Total operating expenses

 

 

4,964

 

 

 

4,900

 

 

 

9,971

 

 

 

9,358

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(Loss) income from operations

 

 

(747

)

 

 

400

 

 

 

(344

)

 

 

997

 

Other expense, net

 

 

23

 

 

 

91

 

 

 

30

 

 

 

188

 

(Loss) income from operations before (benefit from) provision for income taxes

 

 

(770

)

 

 

309

 

 

 

(374

)

 

 

809

 

(Benefit from) provision for income taxes

 

 

(118

)

 

 

12

 

 

 

32

 

 

 

25

 

Net (loss) income

 

$

(652

)

 

$

297

 

 

$

(406

)

 

$

784

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net (loss) income per share:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

$

(0.07

)

 

$

0.03

 

 

$

(0.04

)

 

$

0.08

 

Diluted

 

$

(0.07

)

 

$

0.03

 

 

$

(0.04

)

 

$

0.07

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average shares used in computing net (loss) income per share:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

 

10,027

 

 

 

9,922

 

 

 

9,948

 

 

 

9,943

 

Diluted

 

 

10,027

 

 

 

10,411

 

 

 

9,948

 

 

 

10,469

 

 


IRIDEX Corporation

Condensed Consolidated Balance Sheets

(In thousands)

(unaudited)

 

 

 

July 4,

 

 

January 3,

 

 

 

2015

 

 

2015

 

Assets

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

12,203

 

 

$

13,303

 

Accounts receivable, net

 

 

7,319

 

 

 

8,337

 

Inventories

 

 

10,171

 

 

 

9,119

 

Prepaid expenses and other current assets

 

 

615

 

 

 

510

 

Deferred income taxes - current

 

 

1,625

 

 

 

1,625

 

Total current assets

 

 

31,933

 

 

 

32,894

 

Property and equipment, net

 

 

1,079

 

 

 

735

 

Intangible assets, net

 

 

276

 

 

 

284

 

Goodwill

 

 

533

 

 

 

533

 

Deferred income taxes - long term

 

 

7,151

 

 

 

7,151

 

Other long-term assets

 

 

195

 

 

 

221

 

Total assets

 

$

41,167

 

 

$

41,818

 

 

 

 

 

 

 

 

 

 

Liabilities and Stockholders' Equity

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

2,060

 

 

$

1,758

 

Accrued compensation

 

 

1,470

 

 

 

1,863

 

Accrued expenses

 

 

1,806

 

 

 

1,770

 

Accrued warranty

 

 

520

 

 

 

469

 

Deferred revenue

 

 

1,199

 

 

 

1,179

 

Total current liabilities

 

 

7,055

 

 

 

7,039

 

 

 

 

 

 

 

 

 

 

Long-term liabilities:

 

 

 

 

 

 

 

 

Other long-term liabilities

 

 

881

 

 

 

1,043

 

Total liabilities

 

 

7,936

 

 

 

8,082

 

 

 

 

 

 

 

 

 

 

Stockholders' equity:

 

 

 

 

 

 

 

 

Common stock

 

 

110

 

 

 

108

 

Additional paid-in capital

 

 

38,410

 

 

 

38,511

 

Accumulated deficit

 

 

(5,289

)

 

 

(4,883

)

Total stockholders' equity

 

 

33,231

 

 

 

33,736

 

Total liabilities and stockholders' equity

 

$

41,167

 

 

$

41,818